Table 2 |
|||||
|
Effect of antisense Bcl-xL oligodeoxynucleotides on chemosensitivity in BT-474, ZR-75-1, and MDA-MB-231 breast cancer cells |
|||||
|
Cell line |
Drug |
IC50 (μM)a |
Fold increase in AS Bcl-xL |
||
|
|
|||||
|
Control |
Sense Bcl-xLb |
AS Bcl-xLb |
|||
|
|
|||||
|
BT-474 |
AS Bcl-xL |
4.0 |
-- |
-- |
-- |
|
DOX |
1.0 |
0.92 |
0.68 |
1.5 |
|
|
MMC |
1.4 |
1.32 |
0.88 |
1.6 |
|
|
TXL |
2.4 |
2.2 |
1.34 |
1.8 |
|
|
TXT |
0.54 |
0.51 |
0.26 |
2.1 |
|
|
ZR-75-1 |
AS Bcl-xL |
1.8 |
-- |
-- |
-- |
|
DOX |
0.54 |
0.51 |
0.71 |
1.3 |
|
|
MMC |
0.84 |
0.79 |
0.39 |
2.2 |
|
|
TXL |
1.9 |
1.8 |
1.2 |
1.6 |
|
|
TXT |
3.1 |
3.0 |
1.7 |
1.8 |
|
|
MDA-MB-231 |
AS Bcl-xL |
2.2 |
-- |
-- |
-- |
|
DOX |
0.19 |
0.18 |
0.076 |
2.5 |
|
|
MMC |
0.68 |
0.65 |
0.19 |
3.6 |
|
|
TXL |
2.8 |
2.6 |
0.96 |
2.9 |
|
|
TXT |
1.2 |
1.1 |
0.62 |
1.9 |
|
|
|
|||||
|
AS, antisense; DOX, doxorubicin; IC50, concentration for 50% inhibition; MMC, mitomycin C; TXL, paclitaxel; TXT, docetaxel. aThe data are the means of three separate experiments (SD < 5%); bcells were treated with 1 μM sense Bcl-xL or antisense Bcl-xL. |
|||||
|
Emi et al. Breast Cancer Research 2005 7:R940 doi:10.1186/bcr1323 |
|||||
